Literature DB >> 18521065

Human hepatocellular carcinoma expresses specific PCNA isoforms: an in vivo and in vitro evaluation.

Annamaria Venturi1, Fabrizio Dal Piaz, Catia Giovannini, Laura Gramantieri, Pasquale Chieco, Luigi Bolondi.   

Abstract

Proliferating cell nuclear antigen (PCNA) is a 36 kDa protein involved in several cellular mechanisms, including DNA synthesis and repair, cell cycle regulation and apoptosis. An alteration in PCNA structure might contribute to DNA-damage accumulation in cancer cells. This study was aimed to evaluate the PCNA pattern of expression, in terms of aggregation status, isoforms and post-translational modifications, in human hepatocellular carcinoma (HCC) and cirrhosis as well as in HCC cell lines. Twelve HCCs and surrounding cirrhotic tissues were analysed, along with HepG2, Hep3B and SNU-398 cell lines. Normal liver specimens and cirrhosis without HCC were included as controls. Both DNA-bound and DNA-unbound PCNA fractions were analysed, and PCNA pattern of expression was displayed on two-dimensional gel electrophoresis followed by western blot. Results were confirmed by mass spectrometry. To compare HCCs vs surrounding tissues, immunolabelling and immunostaining were performed. In 6 of 12 HCCs and in cell lines, we found three major PCNA acidic forms, corresponding to monomers, probably dimers and trimers, and a basic isoform. In the six remaining HCCs, only a PCNA acidic form associated with multiple basic isoforms was detected. Importantly, the PCNA basic form was not found in cirrhotic tissues. To clarify the nature of the detected PCNA isoforms, ubiquitin-specific immunoblotting as well as phosphatase treatment were employed. A PCNA-ubiquitylated form in cell lines and PCNA-phosphorylated isoforms in 6 of 12 HCCs were detected. Finally, in the DNA-bound fraction we detected only an acidic PCNA monomeric form. We conclude that human hepatocellular carcinoma expresses specific PCNA isoforms compared to those found in cirrhosis, implicating a role for PCNA functional alterations in hepatocarcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18521065     DOI: 10.1038/labinvest.2008.50

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  11 in total

1.  Elevated expression of cancer-associated proliferating cell nuclear antigen in high-grade prostatic intraepithelial neoplasia and prostate cancer.

Authors:  Xiaoyan Wang; Robert J Hickey; Linda H Malkas; Michael O Koch; Lang Li; Shaobo Zhang; George E Sandusky; David J Grignon; John N Eble; Liang Cheng
Journal:  Prostate       Date:  2010-10-28       Impact factor: 4.104

2.  A Peptide mimicking a region in proliferating cell nuclear antigen specific to key protein interactions is cytotoxic to breast cancer.

Authors:  Shanna J Smith; Long Gu; Elizabeth A Phipps; Lacey E Dobrolecki; Karla S Mabrey; Pattie Gulley; Kelsey L Dillehay; Zhongyun Dong; Gregg B Fields; Yun-Ru Chen; David Ann; Robert J Hickey; Linda H Malkas
Journal:  Mol Pharmacol       Date:  2014-12-05       Impact factor: 4.436

3.  Validating the disruption of proliferating cell nuclear antigen interactions in the development of targeted cancer therapeutics.

Authors:  Shanna J Smith; Robert J Hickey; Linda H Malkas
Journal:  Cancer Biol Ther       Date:  2016-02-18       Impact factor: 4.742

4.  Inhibitory and ameliorative effect of heliomycin derived from actinomycete on induced hepatocellular carcinoma in rats.

Authors:  Ahmed S Alazzouni; Abdulla A Mahmoud; Mohamed M Omran; Ehab A Essawy; Mohga S Abdalla; Mohamed S Abdelfattah
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-01-08       Impact factor: 3.000

5.  Potential Antitumor Activity and Apoptosis Induction of Glossostemon bruguieri Root Extract against Hepatocellular Carcinoma Cells.

Authors:  Mona S Alwhibi; Mahmoud I M Khalil; Mohamed M Ibrahim; Gehan A El-Gaaly; Ahmed S Sultan
Journal:  Evid Based Complement Alternat Med       Date:  2017-03-22       Impact factor: 2.629

Review 6.  Targeting Non-Oncogene Addiction for Cancer Therapy.

Authors:  Hae Ryung Chang; Eunyoung Jung; Soobin Cho; Young-Jun Jeon; Yonghwan Kim
Journal:  Biomolecules       Date:  2021-01-20

7.  Hepatocarcinogenesis Prevention by Pirfenidone Is PPARγ Mediated and Involves Modification of Nuclear NF-kB p65/p50 Ratio.

Authors:  Jorge Antonio Silva-Gomez; Marina Galicia-Moreno; Ana Sandoval-Rodriguez; Hipolito Otoniel Miranda-Roblero; Silvia Lucano-Landeros; Arturo Santos; Hugo Christian Monroy-Ramirez; Juan Armendariz-Borunda
Journal:  Int J Mol Sci       Date:  2021-10-21       Impact factor: 5.923

Review 8.  Novel Peptide Therapeutic Approaches for Cancer Treatment.

Authors:  Caroline M Li; Pouya Haratipour; Robert G Lingeman; J Jefferson P Perry; Long Gu; Robert J Hickey; Linda H Malkas
Journal:  Cells       Date:  2021-10-27       Impact factor: 6.600

9.  Reconstructing dynamic gene regulatory networks from sample-based transcriptional data.

Authors:  Hailong Zhu; R Shyama Prasad Rao; Tao Zeng; Luonan Chen
Journal:  Nucleic Acids Res       Date:  2012-09-21       Impact factor: 16.971

10.  GTSE1, CDC20, PCNA, and MCM6 Synergistically Affect Regulations in Cell Cycle and Indicate Poor Prognosis in Liver Cancer.

Authors:  Yongchang Zheng; Yue Shi; Si Yu; Yuanyuan Han; Kai Kang; Haifeng Xu; Huajian Gu; Xinting Sang; Yang Chen; Jingyu Wang
Journal:  Anal Cell Pathol (Amst)       Date:  2019-12-30       Impact factor: 2.916

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.